Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study. 

Novel method identifies undiagnosed drug-induced liver injury in cancer patients

27 Jul 2020

Researchers have recently developed a reliable and simple method to identify undiagnosed drug-induced liver injury (DILI) among cancer patients, reporting an annual incidence of 0.69 percent of chemotherapy-related liver injury among those admitted to an oncology department.

To establish such method and to assess current clinical approach to elevated laboratory liver test results, the researchers identified 289 patients admitted to an oncology department who had systemic chemotherapy episodes for cancer treatment from 1 January 2017 to 31 December 2017.

Hy’s law was applied to laboratory liver test results, with aid of healthcare information system, to identify potential hepatocellular DILI cases. The researchers then performed a medical record review among identified patients to exclude liver dysfunction of alternative causes. Moreover, the current clinical approach to elevated laboratory liver tests was assessed through medical record review.

One hundred twenty-three of 289 patients who were treated with systemic chemotherapies were found to have elevated laboratory liver tests. Of the identified patients, eight were suspected as potential Hy’s law cases.

Two patients were found to have chemotherapy-associated liver injury due to 5-fluorouracil, leucovorin, irinotecan, and S-1 plus paclitaxel separately after medical review. Seven (87.5 percent) of eight potential Hy’s law cases were prescribed with at least two kinds of liver protectants and remained treated with traditional Chinese medicine for decoction.

In another study that also developed a highly sensitive model to identify DILI patients at increased risk of acute liver failure (ALF), the authors concluded that Hy’s Law identified patients with DILI at high risk for ALF with low sensitivity but high specificity. [Clin Gastroenterol Hepatol 2015;13:2360-2368]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.